This study reports the results of a questionnaire survey of female members of the British Epilepsy Association (BEA). The women were asked about their concerns about their epilepsy with respect to being female, and, in particular, asked about the information they had been given on important topics such as contraception and pregnancy. A questionnaire was sent to 6000 BEA female members of whom 1855 (31 %) replied. Forty-six percent of the women (mainly aged between 26 and 45) stated that they currently used some form of contraception. The most frequently used method was the condom (34 %). Twenty-two percent of the women using contraception were taking the oral contraceptive pill whilst a further 4 % were using a hormonal contraceptive injection. Fifty-one percent of the women aged between 16 and 55 claimed not to have received any advice about possible interactions between contraception and antiepileptic drug therapy. With regards to pregnancy, 34 % claimed they had not received any advice and 25 % had not discussed pregnancy with anyone. The women planning to have children over the subsequent 2 years received the greatest amount of advice about epilepsy and pregnancy, although 20 % still claimed not to have received any information. Thirty-four percent of the women in the study stated that they were either menopausal or post-menopausal. Twenty-nine percent of women who had taken hormone replacement therapy in the past reported an increase in seizure frequency compared with 18 % amongst current users. This survey has shown that women with epilepsy want, and need, more information and counselling about issues relating to contraception, pregnancy and the menopause.
Introduction
Until recently, the management of patients with seizures took no account of gender, despite the fact that about 50 % of people with epilepsy are female. Epilepsy for a woman is not the same as epilepsy for a man. In particular, in women, epilepsy affects sexual development, sexuality, the menstrual cycle, aspects of contraception, fertility, the developing foetus and pregnancy, the mother-child relationship and the menopause, in ways that are unique to their sex. Therefore, the British Epilepsy Association (BEA) undertook a survey of its female members, asking about their concerns about their epilepsy with respect to being female, and in particular asking about the information they had received on important topics such as contraception and pregnancy.
Materials and Methods
A questionnaire was designed in consultation with Taylor Nelson Sofres Healthcare, an independent market research agency, and was sent to 6000 BEA female members. Not all these women would have had epilepsy, some would have been carers, others friends, etc. Only females with epilepsy aged 16 or above were asked to fill in the questionnaire. This questionnaire was devised following qualitative research with women with epilepsy that was conducted by Taylor Nelson Sofres Healthcare.
Results
Data in the study are based on the 1855 (31 %) questionnaires which were returned by the cut-off date for inclusion in the study.
Patient demographics
The age of the respondents is summarized in Table 1,  their treatment in Table 2 and the length of time since onset of their epilepsy in Table 3 . Of the women, 1276 (64 %) were of child-bearing age, i.e. between the ages of 16 and 45. The marital status of the respondents is summarized in Table 4 . Eight hundred and eighty (47 %) women had had children: 292 (17 %) currently had children under the age 10.
One thousand and ninety-three (59 %) women were attending a hospital clinic for their epilepsy.
Contraception
Eight hundred and forty-seven (46 %) women (mainly aged between 26 and 45) stated that they currently used some form of contraception ( Table 5 ). The most frequently used method was the condom (290 (34 %) of those using contraception). One hundred and eightynine (22 %) of the women using contraception were taking the oral contraceptive pill, whilst a further 40 (4 %) were using a hormonal contraceptive injection. Amongst the women using contraception, 83 (16 %) women on enzyme-inducing antiepileptic drugs were taking the oral contraceptive pill compared with 130 (27 %) on non-enzyme-inducing antiepileptic drug therapy.
General practitioners and hospital specialists were equally likely to provide information regarding contraception. However, 948 (51 %) women claimed not to have received any advice about possible interactions between contraception and antiepileptic drug therapy (Table 6 ). Of those using the oral contraceptive pill (n = 189), 31 (16 %) claimed not to have been given any advice whilst 81 (43 %) of the women indicated they had been given information regarding reduced effectiveness of the contraceptive pill (Table 7) . Sixty-nine women (37 %) on the oral contraceptive pill were taking an increased dose, and 32 (17 %) of these women stated that they were concerned about taking this higher dose. Eighty-nine (47 %) women taking the oral contraceptive pill felt that they had not been given enough information about the contraceptive pill and their medication.
Pregnancy
Eight hundred and eighty (47 %) of the women already had children, but one in 10 of these were planning to have further children. Overall, 441 (23 %) of the women were planning to have children, 169 (9 %) within the next 2 years (Table 8) .
The women were asked about the advice they had received about pregnancy (Table 9) . Six hundred and thirty-seven (34 %) claimed they had not received any advice and 459 (25 %) had not discussed pregnancy with anyone. Amongst those who had already had children, 232 (38 %) claimed not to have received any advice about pregnancy and epilepsy and only 210 (24 %) had discussed the issues with a doctor before conception. The women planning to have children over the subsequent 2 years received the greatest amount of advice about epilepsy and pregnancy, although 34 (20 %) still claimed not to have received any advice. Many women intending to have children in the next 2 years felt they still had unanswered questions relating to their epilepsy and pregnancy and subsequent care of the child (Table 10 ). The best informed group comprised those women who had already had children and planned to have more. In the main, advice was given by hospital specialists (Table 11) . Fifty-eight percent of the women receiving advice stated that this was their main source of information. General practitioners were mentioned by a third. Of all the women who received advice, 17 % were advised by the BEA (which might be expected in this group of BEA members).
Overall, the women felt there was a need for more information about epilepsy and pregnancy.
Menopause
Six hundred and twenty (34 %) of the women in the study stated that they were either menopausal or postmenopausal. One hundred and eighty-eight (30 %) menopausal and post-menopausal women were currently taking hormone replacement therapy (HRT). A further 97 (16 %) of the women had taken hormone replacement therapy in the past.
Twenty-eight (29 %) women who had taken hormone replacement therapy in the past reported an increase in seizure frequency compared with 33 (18 %) amongst current users (Table 12) .
Discussion
Although a large number of women returned the questionnaire, they were not wholly representative of women with epilepsy. The women respondents tended to have had a more severe seizure disorder in that only 34 % had well-controlled epilepsy. Community-based audit studies of epilepsy suggest that about 60 % of women with a history of epilepsy are in remission and are seizure-free 1, 2 . Fifty-nine percent of the women who returned the questionnaire were currently being followed-up in a hospital outpatient clinic compared with 48 % from a recent community study 1 . Despite this, many women in this study had received what they perceived to be inadequate or no information about contraception or pregnancy in connection with their seizure disorder. These are obviously issues of considerable importance to women of childbearing age.
Despite knowledge for many years that the interactions between the combined oral contraceptive pill and enzyme-inducing antiepileptic drugs can lead to contraceptive failure, many doctors seem unaware of the need to increase the dose of the contraceptive pill when such drugs are prescribed together. A recent survey in the USA showed that less than half of the neurologists and obstetricians who replied knew that changes in the dose of oral contraceptive pill might be indicated when prescribing antiepileptic drugs in addition to an oral contraceptive pill. Only 4 % of neurologists and none of the obstetricians were correct in identifying the interactions between the combined oral contraceptive pill and phenytoin, carbamazepine, sodium valproate, phenobarbitone, primidone and ethosuximide. Not surprisingly, 27 % of neurologists and 21 % of obstetricians reported contraceptive failures amongst their patients taking antiepileptic drugs 3 .
In the last decade there have been several advances in the management of women with epilepsy who wish to have children. The most important of these has been the advent of pre-conception counselling. It is recognized that about 1 in 10 people labelled as having a seizure disorder is incorrectly diagnosed. So when a woman with epilepsy first sees a doctor to discuss starting a family, it is important (as at other times) to reconsider the diagnosis and to review drug therapy. One of the more important issues is that of antiepileptic drug therapy. The risk of foetal malformation is increased if a woman is on polytherapy, particularly if sodium valproate is part of the combination. The aim of drug therapy is to put the woman on the lowest possible dosage of the most appropriate drug that will control her seizures. All the older antiepileptic drugs (carbamazepine, sodium valproate, phenytoin and barbiturates) are teratogenic in both humans and animals, showing similar patterns of malformation. Some of the newer antiepileptic drugs such as lamotrigine, gabapentin and tiagabine do not appear to be teratogenic in animal studies, so in the future, these may be the therapies of choice for women of childbearing age 4 . Data are currently being collected about newer antiepileptic drugs and their safety in pregnancy 5 .
The genetics of the seizure disorder, breast-feeding and issues of child care and epilepsy need to be discussed. High dose folate supplements (5 mg) for 1 month before, and for the first 3 months of pregnancy are recommended for women with epilepsy as there is a high risk of spina bifida in the foetus exposed to carbamazepine or sodium valproate 4 . Very few of the women respondents were aware of the need to take folic acid before, and for the first 3 months after conception.
Over half the women who returned the questionnaire felt that they had not been provided with enough information about pregnancy; in particular, few had received information about teratogenicity of antiepileptic drugs or the need for pre-conception counselling.
There is very little information about epilepsy and the menopause. In this study, in about a fifth of menopausal and post-menopausal women, seizures became less frequent. There are also scanty data relating to women with epilepsy and HRT. Theoretically, treatment with oestrogens may increase seizure frequency in some women with epilepsy 6 . The data from this study would support this in that compared with women who had not taken HRT, double the number of past users of HRT reported an increase in seizure frequency at the menopause. On the other hand, treatment with enzymeinducing antiepileptic drugs predisposes towards osteoporosis and osteomalacia. An increased incidence of fractures has been reported, both related and unrelated to seizures 7 . It therefore seems sensible for a menopausal woman to try HRT, but with the warning that the HRT may exacerbate her seizure disorder. This is an area which needs further research.
This study has shown that women with epilepsy want, and need, far more information and counselling about contraception, pregnancy and the menopause.
